Diagnostic Products Corp. to launch CAM 17.1 pancreatic cancer assay in Europe this month.
This article was originally published in The Gray Sheet
DIAGNOSTIC PRODUCTS CAM 17.1 PANCREATIC CANCER ASSAY EUROPEAN LAUNCH slated for April, the Los Angeles, California immunodiagnostic firm says. The assay will allow physicians to "quickly and economically assess the patient for pancreatic cancer, allowing immediate follow up when the test result is positive and reducing the need for more expensive medical imaging," DPC says in a March 21 release.
You may also be interested in...
A combined final opinion on the European Chemicals Agency’s proposed microplastic restriction is expected from ECHA committees by year-end, at which point the European Commission will consider whether and when microplastic must be removed from all leave-on cosmetic products marketed in the EU.
Butterfly Network’s CEO Laurent Faracci outlines the company’s growth strategy and plans for their “ultrasound-on-a-chip” technology after its merger with blank check company Longview Acquisition Corp. See what the company’s CEO said about it here.
CDC’s Advisory Committee on Immunization Practices votes 13-1 that these two groups be first in line for vaccination once FDA authorizes a vaccine and ACIP recommends it. Goal of vote is to guide health departments in placing vaccine orders.